3 Drugs Stocks Pushing The Industry Higher
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
All three major indices are trading down today with the
Dow Jones Industrial Average
(
^DJI
) trading down 123 points (-0.7%) at 17,854 as of Tuesday, March 17, 2015, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,105 issues advancing vs. 1,894 declining with 134 unchanged.
The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.4%. Top gainers within the industry include
(
), up 3.3%, and
Teva Pharmaceutical Industries
(
), up 0.9%. On the negative front, top decliners within the industry include
(
), down 1.7%,
(
), down 1.3%,
Valeant Pharmaceuticals International
(
), down 1.0%,
(
), down 1.1% and
(
), down 1.1%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.27 (0.6%) to $48.89 on average volume. Thus far, 938,157 shares of Sanofi exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $48.55-$49.04 after having opened the day at $48.71 as compared to the previous trading day's close of $48.62.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Sanofi discovers, develops, and distributes therapeutic solutions. Sanofi has a market cap of $124.2 billion and is part of the health care sector. Shares are up 6.6% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Sanofi
as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, growth in earnings per share and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is up $3.00 (2.4%) to $129.43 on average volume. Thus far, 826,144 shares of Mallinckrodt exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $126.46-$130.35 after having opened the day at $126.75 as compared to the previous trading day's close of $126.43.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. Mallinckrodt has a market cap of $14.5 billion and is part of the health care sector. Shares are up 27.7% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Mallinckrodt a buy, no analysts rate it a sell, and 3 rate it a hold.
TheStreet Ratings rates
Mallinckrodt
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $2.47 (1.4%) to $180.97 on average volume. Thus far, 630,776 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $176.76-$181.87 after having opened the day at $178.09 as compared to the previous trading day's close of $178.50.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $35.8 billion and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Alexion Pharmaceuticals
as a
. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
Alexion Pharmaceuticals Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null